<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581772</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-F-0002</org_study_id>
    <nct_id>NCT04581772</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Open-Label, Randomized, Crossover Study to Evaluate the Bioavailability, Effect of Food, Palatability, and Safety of Various DNL343 Oral Formulations in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 relative bioavailability study carried out in approximately 24 healthy male&#xD;
      subjects and healthy female subjects of non childbearing potential to investigate the effects&#xD;
      of formulation and food on the safety, tolerability, and pharmacokinetics (PK) of DNL343.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Actual">June 4, 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameter: Maximum observed concentration (Cmax) of DNL343 in plasma</measure>
    <time_frame>Up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Time to maximum observed concentration (Tmax) of DNL343 in plasma</measure>
    <time_frame>Up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Area under the concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of DNL343 in plasma</measure>
    <time_frame>Up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL343 in plasma</measure>
    <time_frame>Up to 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Maximum observed concentration (Cmax) of DNL343 in plasma in the fed versus fasted states</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Time to maximum observed concentration (Tmax) of DNL343 in plasma in the fed versus fasted states</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Area under the concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of DNL343 in plasma in the fed versus fasted states</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL343 in plasma in the fed versus fasted states</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL343</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL343</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥18.5 to &lt; 30 kg/m2 and body weight of at least 50 kg&#xD;
&#xD;
          -  For women: Must have been surgically sterilized or be postmenopausal.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant endocrine, pulmonary, cardiovascular,&#xD;
             gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or&#xD;
             allergic disease, or other major disorders&#xD;
&#xD;
          -  History of malignancy, except fully resected basal cell carcinoma&#xD;
&#xD;
          -  History of clinically significant neurologic or psychiatric diseases; head trauma with&#xD;
             loss of consciousness; or clinically significant depression or suicidal ideation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Tsai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd.</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

